Sweden's leading cancer hospital, linked to the Karolinska Institutet and Nobel Assembly, with strong registry-based research.
Karolinska University Hospital in Stockholm is Sweden's leading cancer hospital, linked to the Karolinska Institutet and the Nobel Assembly, and ranks thirty-ninth in the Newsweek/Statista oncology list. Its Comprehensive Cancer Centre is known for registry-based research, because Sweden's national quality registries make real-world evidence and registry-randomised trials possible, and it collaborates with the Skandion proton clinic in Uppsala; Per Hall, Jonas Bergh and Thomas Helleday are among the people OnCo lists. OnCo links it to the ALASCCA aspirin trial, to the Swedish registry study of HPV vaccination and cervical cancer, and to ideas on randomising inside cancer registries and a registry-based MCED trial. Whether registry designs can carry regulatory weight outside the Nordics is the open question. Its registry and haematology programmes are listed below.
From OpenAlex, oncology works in the last five years (2022 to 2026, current year in progress); counted on 2026-09-24.
Matched to Karolinska University Hospital, including child institutions. 990 works · 12,624 citations · 82% open access · 11% clinical trials · 2% reviews.
Hans-Gustaf Ljunggren proposed the missing-self hypothesis of NK cell recognition.
Jonas Bergh is a breast oncologist and long-standing leader of Swedish and European breast cancer trials.
Patrik Rossi represents Karolinska University Hospital in the Organisation of European Cancer Institutes, which lists the centre among its members in Sweden.
Per Hall is the epidemiologist behind KARMA and the risk-based breast screening programme.
Rolf Kiessling is the immunologist who first described natural killer cells.
Co-discovered that PARP inhibitors kill BRCA-deficient cells, the synthetic lethality behind olaparib and its successors.
Screening programmes short of radiologists can read this as prospective evidence that a well-validated AI reader can take the second reader's seat without lowering cancer detection. It is a paired-reader study in one hospital, not a randomised trial, so MASAI and real-world follow-up carry the argument further.
Vaccinating girls before they are exposed to HPV prevents most cervical cancers. Catch-up vaccination in young adults still helps, but less. Combined with HPV screening, elimination of cervical cancer as a public health problem is a realistic goal.
The origin of short-course preoperative radiotherapy, still the standard schedule across northern Europe and the backbone of the RAPIDO regimen 24 years later.
Shares Per Hall, Artificial intelligence for breast cancer detection in screening mammography in Sweden: a prospective, population-based, paired-reader, non-inferiority study (ScreenTrustCAD).
Shares Capio S:t Göran's Hospital, Organisation of European Cancer Institutes.
Shares Örebro University Hospital, Organisation of European Cancer Institutes.
Shares Artificial intelligence for breast cancer detection in screening mammography in Sweden: a prospective, population-based, paired-reader, non-inferiority study (ScreenTrustCAD), ScreenTrustCAD.
Shares Hans-Gustaf Ljunggren, Rolf Kiessling.
Shares Linköping University Hospital Cancer Center, Organisation of European Cancer Institutes.
Shares Artificial intelligence for breast cancer detection in screening mammography in Sweden: a prospective, population-based, paired-reader, non-inferiority study (ScreenTrustCAD), ScreenTrustCAD.
Open-source projects that this organisation maintains, from OnCo's own catalogue: licence and last activity as the repository reported them on the day of the fetch. Listing is not endorsement; check the licence before reuse and the validation before clinical use.
Clinical Genomics Stockholm's accredited pipeline for somatic variant calling on tumour panels and whole genomes.